Effect of Lixelle on upper limb disorders

Phase 4

• Conditions: Dialysis related amyloidosis; amyloidosis; D000686

• Registration Number: JPRN-jRCTs032180390
• Lead Sponsor: Tsuchiya Ken

Brief Summary

Fifteen hemodialysis patients were treated with Lixelle for one year. As a result, one year after using Lixelle, the range of motion of the shoulder joint and TUAGT improved. It was considered that the use of Lixelle improved joint inflammation and increased the range of motion of the shoulder joint. In addition, it was considered that the improvement of TUAGT was obtained by improving the inflammation of the hip joint as well as the shoulder joint.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-20
• Study Completion: 2020-10-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Patients satisfying insurance application criteria of Lixelle (over 10 years of dialysis history, history of carpal tunnel opening procedure, confirmation of bone cysts, amyloid deposition, pain)

Exclusion Criteria

Patients who underwent open carpal tunnel within 3 months
Patients who can not answer the DASH questionnaire
Patients judged inappropriate by the research director

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in DASH score

Secondary Outcome Measures

Name	Time	Method
Change in grip strength <br>Change in pain <br>Change in TUAGT <br>Change in range of motion of joint <br>Changes in blood collection data